TORONTO, CANADA — (March 27, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) is pleased to announce today that its founder and Chief Scientific Officer, Dr. John Wallace, is to receive the Horace W. Davenport Distinguished Lectureship in honour of his distinguished lifetime achievement in gastrointestinal and liver physiological research. This award is granted by the American Physiological Society (“APS”) and is the most prestigious award of the APS Gastrointestinal & Liver Physiology Section.
John Wallace commented, “I am very honoured to receive this award. It is remarkable that the first work I ever did related to the digestive system was a term paper in my final year of high school, based on the research of Horace Davenport. It was his research that stimulated me to pursue medical science as a career.”
John will receive the award at the upcoming Experimental Biology conference on April 25th, 2017 in Chicago, Illinois. John will also be giving a lecture a week prior to that conference at the University of Massachusetts.
In connection with Antibe’s recently announced regional licensing deal with Laboratoires Acbel SA, Antibe issued 240,000 common shares and 120,000 common share purchase warrants (with a $0.22 exercise price and 2-year expiry) to Knight Therapeutics Inc. (“Knight”) in exchange for the return of the ATB-346 territory rights to Romania (previously granted to Knight in November 2015). The securities issued are subject to a four-month statutory hold period and a TSX Venture Exchange hold period, each expiring on July 28, 2017.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product sales, engaging new distributors and independent representatives, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.
Contact Information
Antibe Therapeutics Inc.
Dan Legault
Chief Executive Officer
Tel: +1 416-473-4095
dan.legault@antibethera.com
Read all news